Zhou You, Zheng Xiao, Chen Lu-Jun, Xu Bin, Jiang Jing-Ting
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, Soochow University, Changzhou, 213003, China.
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Jiangsu Engineering Research Center for Tumor Immunotherapy, Institute of Cell Therapy, Soochow University, Changzhou, 213003, China.
Pathol Res Pract. 2019 Feb;215(2):335-342. doi: 10.1016/j.prp.2018.12.009. Epub 2018 Dec 11.
The aim of the study was to measure the expression of microRNA (miR)-181b in patients with lung cancer, investigate its biological function and elucidate the underlying mechanisms associated with the development of lung cancer.
miR-181b expression in tissues was measured via RT-qPCR. After A549 cells were transfected with miR-181b mimic or si-Sox6, the proliferation, migration and cell cycle distribution of A549 were evaluated using cell counting kit-8 assay, transwell assay and flow cytometry. The levels of cell cycle-related proteins and Sox6 were analyzed by western blotting. Gene targets of miR-181b were predicted via bioinformatics analysis and verified using a dual-luciferase reporter gene assay.
Expression of miR-181b was significantly downregulated in lung cancer tissues (P < 0.05), and was inversely correlated with the degree of cell differentiation and clinical stages of lung cancer (both P < 0.05). Additionally, the expression of miR-181b was significantly lower in adenocarcinoma compared with squamous cell carcinoma in the lungs (P < 0.05). Overexpression of miR-181b significantly decreased the protein level of Sox6 and significantly suppressed the cell proliferation and metastasis (both P < 0.05); this effect was also observed in A549 cells transfected with si-Sox6. The luciferase activity of a Sox6 3'-untranslated region-based reporter construct was significantly lower when transfected with miR-181b (P < 0.05), which suggests that Sox6 is a direct target of miR-181b.
The results of the present study suggest that miR-181b may function as a tumor inhibitor in the development of lung cancer via targeting Sox6 to decrease the proliferation and metastasis of lung cancer cells.
本研究旨在检测肺癌患者中微小RNA(miR)-181b的表达,探讨其生物学功能,并阐明与肺癌发生发展相关的潜在机制。
通过逆转录定量聚合酶链反应(RT-qPCR)检测组织中miR-181b的表达。用miR-181b模拟物或小干扰RNA(si)-Sox6转染A549细胞后,使用细胞计数试剂盒-8法、Transwell法和流式细胞术评估A549细胞的增殖、迁移和细胞周期分布。通过蛋白质印迹法分析细胞周期相关蛋白和Sox6的水平。通过生物信息学分析预测miR-181b的基因靶点,并使用双荧光素酶报告基因检测进行验证。
miR-181b在肺癌组织中的表达显著下调(P<0.05),且与肺癌细胞分化程度和临床分期呈负相关(均P<0.05)。此外,肺腺癌中miR-181b的表达明显低于肺鳞癌(P<0.05)。miR-181b过表达显著降低Sox6蛋白水平,并显著抑制细胞增殖和转移(均P<0.05);在转染si-Sox6的A549细胞中也观察到了这种效应。当用miR-181b转染时,基于Sox6 3'-非翻译区的报告基因构建体的荧光素酶活性显著降低(P<0.05),这表明Sox6是miR-181b的直接靶点。
本研究结果表明,miR-181b可能通过靶向Sox6降低肺癌细胞的增殖和转移,在肺癌发生发展中发挥肿瘤抑制作用。